Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy
A Katz, LM Shulman, A Porgador, M Revel… - Journal of …, 1993 - journals.lww.com
We investigated the antitumor effects of human recombinant interleukin-6 (hrIL-6) on the
highly metastatic B16 melanoma clone F10. 9. These tumor cells were found to have very
low levels of IL-6 receptors and in vitro IL-6 had no effect on cell proliferation or on the
expression of MHC class I antigens. However, in vivo IL-6 was active against the metastatic
growth of this tumor in mice, presumably through indirect immune effects. Low-dose IL-6 (1-
10 ug/day), in three daily injections, 4 days a week, for 3 weeks, strongly inhibited the …
highly metastatic B16 melanoma clone F10. 9. These tumor cells were found to have very
low levels of IL-6 receptors and in vitro IL-6 had no effect on cell proliferation or on the
expression of MHC class I antigens. However, in vivo IL-6 was active against the metastatic
growth of this tumor in mice, presumably through indirect immune effects. Low-dose IL-6 (1-
10 ug/day), in three daily injections, 4 days a week, for 3 weeks, strongly inhibited the …
